1. Home
  2. COGT vs KVYO Comparison

COGT vs KVYO Comparison

Compare COGT & KVYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

N/A

Current Price

$26.90

Market Cap

5.5B

Sector

Health Care

ML Signal

N/A

Logo Klaviyo Inc. Series A

KVYO

Klaviyo Inc. Series A

N/A

Current Price

$22.42

Market Cap

4.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
COGT
KVYO
Founded
2014
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.9B
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
COGT
KVYO
Price
$26.90
$22.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
12
23
Target Price
★ $55.82
$27.17
AVG Volume (30 Days)
1.9M
★ 4.6M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 35.29
EPS
N/A
★ N/A
Revenue
$7,871,000.00
★ $1,234,019,000.00
Revenue This Year
N/A
$24.77
Revenue Next Year
$5,819.52
$18.88
P/E Ratio
★ N/A
$657.67
Revenue Growth
N/A
★ 31.63
52 Week Low
$26.36
$12.53
52 Week High
$43.73
$33.36

Technical Indicators

Market Signals
Indicator
COGT
KVYO
Relative Strength Index (RSI) 36.08 60.96
Support Level N/A $15.49
Resistance Level $37.34 $23.52
Average True Range (ATR) 1.77 1.24
MACD -0.36 -0.05
Stochastic Oscillator 6.38 65.93

Price Performance

Historical Comparison
COGT
KVYO

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

Share on Social Networks: